87 related articles for article (PubMed ID: 31077425)
1. Therapeutic concentration achievement and allograft survival comparing usage of conventional tacrolimus doses and CYP3A5 genotype-guided doses in renal transplantation patients.
Anutrakulchai S; Pongskul C; Kritmetapak K; Limwattananon C; Vannaprasaht S
Br J Clin Pharmacol; 2019 Sep; 85(9):1964-1973. PubMed ID: 31077425
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of CYP3A5 genotype-guided tacrolimus dosing in solid organ transplantation using real-world data.
Deininger KM; Anderson HD; Patrinos GP; Mitropoulou C; Aquilante CL
Pharmacogenomics J; 2024 May; 24(3):14. PubMed ID: 38750044
[TBL] [Abstract][Full Text] [Related]
3. Tools for a personalized tacrolimus dose adjustment in the follow-up of renal transplant recipients. Metabolizing phenotype according to CYP3A genetic polymorphisms versus concentration-dose ratio.
Vidal-Alabró A; Colom H; Fontova P; Cerezo G; Melilli E; Montero N; Coloma A; Manonelles A; Favà A; Cruzado JM; Torras J; Grinyó JM; Lloberas N
Nefrologia (Engl Ed); 2024; 44(2):204-216. PubMed ID: 38614890
[TBL] [Abstract][Full Text] [Related]
4. CYP3A5 Genotype-Dependent Drug-Drug Interaction Between Tacrolimus and Voriconazole in Chinese Kidney Transplant Patients.
Zhang Y; Du Y; Ren S; Li Y; Zhang X; Cao X; Liu F; Zong H; Li Y
Ann Pharmacother; 2024 Jun; 58(6):605-613. PubMed ID: 37702380
[TBL] [Abstract][Full Text] [Related]
5. CYP3A5 Polymorphisms Leading to Tacrolimus Toxicity Following an Adult Renal Transplant.
Alotaibi N
Saudi J Kidney Dis Transpl; 2023 May; 34(3):250-253. PubMed ID: 38231720
[TBL] [Abstract][Full Text] [Related]
6. CYP3A5 Expressor Genotype of the Transplanted Kidney Increases the Risk of Preterm Graft Loss and Acute Rejection.
Warzyszyńska K; Zawistowski M; Karpeta E; Jałbrzykowska A; Kosieradzki M
Nephron; 2023; 147(7):441-450. PubMed ID: 36630936
[TBL] [Abstract][Full Text] [Related]
7. Tacrolimus and Diabetes in Kidney Transplantation: The Impact of Cyp3a5 Gene Polymorphism.
Liang S; Zhu X; Cai R; Yan B; Liang W; Cai M; Yang P
Transplant Proc; 2023 Dec; 55(10):2398-2402. PubMed ID: 37891021
[TBL] [Abstract][Full Text] [Related]
8. Genotype-Guided Model for Prediction of Tacrolimus Initial Dosing After Lung Transplantation.
Du W; Wang X; Zhang D; Zuo X
J Clin Pharmacol; 2024 Jun; 64(6):719-727. PubMed ID: 38327217
[TBL] [Abstract][Full Text] [Related]
9. Tacrolimus pharmacokinetics are influenced by CYP3A5, age, and concomitant fluconazole in pediatric kidney transplant patients.
Alghamdi A; Seay S; Hooper DK; Varnell CD; Darland L; Mizuno T; Lazear D; Ramsey LB
Clin Transl Sci; 2023 Oct; 16(10):1768-1778. PubMed ID: 37340713
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenomic implications of the differential distribution of CYP3A5 metabolic phenotypes among Latin American populations.
Suarez-Kurtz G; Struchiner CJ
Pharmacogenomics; 2024 Mar; 25(4):187-195. PubMed ID: 38506326
[TBL] [Abstract][Full Text] [Related]
11. Early Tacrolimus Concentrations After Lung Transplant Are Predicted by Combined Clinical and Genetic Factors and Associated With Acute Kidney Injury.
Miano TA; Flesch JD; Feng R; Forker CM; Brown M; Oyster M; Kalman L; Rushefski M; Cantu E; Porteus M; Yang W; Localio AR; Diamond JM; Christie JD; Shashaty MGS
Clin Pharmacol Ther; 2020 Feb; 107(2):462-470. PubMed ID: 31513279
[TBL] [Abstract][Full Text] [Related]
12. HDL-C and creatinine levels at 1 month are associated with patient 12-month survival rate after kidney transplantation.
Teng H; Hu X; Liu N
Pharmacogenet Genomics; 2024 Feb; 34(2):33-42. PubMed ID: 37906625
[TBL] [Abstract][Full Text] [Related]
13. Physiologically based pharmacokinetic model combined with reverse dose method to study the nephrotoxic tolerance dose of tacrolimus.
Cai L; Ke M; Wang H; Wu W; Lin R; Huang P; Lin C
Arch Toxicol; 2023 Oct; 97(10):2659-2673. PubMed ID: 37572130
[TBL] [Abstract][Full Text] [Related]
14. A Population Pharmacokinetic Model to Predict the Individual Starting Dose of Tacrolimus for Tunisian Adults after Renal Transplantation.
Abderahmene A; Francke MI; Andrews LM; Hesselink DA; Amor D; Sahtout W; Ajmi M; Mastouri H; Bouslama A; Zellama D; Omezzine A; De Winter BCM
Ther Drug Monit; 2024 Feb; 46(1):57-66. PubMed ID: 38018879
[TBL] [Abstract][Full Text] [Related]
15. Effects of
Guo Z; Chen Q; Liu J; Li S; Wang H; Tang R; Zhang Z
Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38002088
[TBL] [Abstract][Full Text] [Related]
16. Development of Non-Immunosuppressive FK506 Derivatives as Antifungal and Neurotrophic Agents.
Jung JA; Yoon YJ
J Microbiol Biotechnol; 2020 Jan; 30(1):1-10. PubMed ID: 31752059
[TBL] [Abstract][Full Text] [Related]
17. The TOMATO Study (Tacrolimus Metabolization in Kidney Transplantation): Impact of the Concentration-Dose Ratio on Death-censored Graft Survival.
Jouve T; Fonrose X; Noble J; Janbon B; Fiard G; Malvezzi P; Stanke-Labesque F; Rostaing L
Transplantation; 2020 Jun; 104(6):1263-1271. PubMed ID: 31415035
[TBL] [Abstract][Full Text] [Related]
18. CYP3A5 gene polymorphisms and their impact on dosage and trough concentration of tacrolimus among kidney transplant patients: a systematic review and meta-analysis.
Khan AR; Raza A; Firasat S; Abid A
Pharmacogenomics J; 2020 Aug; 20(4):553-562. PubMed ID: 31902947
[TBL] [Abstract][Full Text] [Related]
19. Impact of CYP3A5 Genetic Polymorphism on Intrapatient Variability of Tacrolimus Exposure in Chinese Kidney Transplant Recipients.
Cheung CY; Chan KM; Wong YT; Chak WL; Bekers O; van Hooff JP
Transplant Proc; 2019; 51(6):1754-1757. PubMed ID: 31255354
[TBL] [Abstract][Full Text] [Related]
20. Avoiding Tacrolimus Underexposure and Overexposure with a Dosing Algorithm for Renal Transplant Recipients: A Single Arm Prospective Intervention Trial.
Francke MI; Andrews LM; Le HL; van de Wetering J; Clahsen-van Groningen MC; van Gelder T; van Schaik RHN; van der Holt B; de Winter BCM; Hesselink DA
Clin Pharmacol Ther; 2021 Jul; 110(1):169-178. PubMed ID: 33452682
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
